Journal of Hematology & Oncology

Article	Citations
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast	689
Helicobacter pylori and gastric cancer: mechanisms and new perspectives	348
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	348
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	347
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma	340
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC	336
Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer	335
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine	307
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence	301
Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML	287
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials	284
Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice	280
Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia	275
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	263
Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer	258
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer	230
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	224
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells	217
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	215
Targeting GPRC5D for multiple myeloma therapy	215
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	211
Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis	207
Emerging role of RNA sensors in tumor microenvironment and immunotherapy	206
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	199
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients	198

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	198
Involvement of inflammasomes in tumor microenvironment and tumor therapies	180
Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study	177
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	171
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders	167
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL	167
Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leuke	167
Gene and cell therapies in China: booming landscape under dual-track regulation	159
Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report	156
Mesenchymal stem/stromal cells in cancer therapy	154
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	151
Applications of single-cell sequencing in cancer research: progress and perspectives	151
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	144
The regulation of insulin receptor/insulin-like growth factor 1 receptor ratio, an important factor for breast cancer prognosis, by TRIP-Br1	139
Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial	139
Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden	139
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	138
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	134
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	129
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	121
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting	120
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena	120
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA	118
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial	118
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia	117
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML	116
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives	109
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	108
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy	106
Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation	104
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium	101
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	100
APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential	99
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy	99
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management	98
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis	97
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents	97
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells	96
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	94
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients	92
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)	91
D-ribose-5-phosphate inactivates YAP and functions as a metabolic checkpoint	89
Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers	88
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy	88
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy	88
A novel non-invasive exhaled breath biopsy for the diagnosis and screening of breast cancer	87
A four-stage model for murine natural killer cell development in vivo	86
Integrins regulate stemness in solid tumor: an emerging therapeutic target	86
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma	85
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma	85

Metabolic reprogramming in the tumor microenvironment of liver cancer	83
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia	82
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	82
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	81
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation	81
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma	81
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies	81
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin	80
Current and future treatment strategies in chronic lymphocytic leukemia	79
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	78
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting	78
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	78
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	77
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)	76
Targeting chemokines for acute lymphoblastic leukemia therapy	75
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1	75
Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting	74
Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma	73
Recent developments in immunotherapy for gastrointestinal tract cancers	73
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021	72
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer	72
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	72
Correction: hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	72
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine	71
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing	71
Correction: A single-cell and spatially resolved atlas of human osteosarcomas	71
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	70
RETRACTED ARTICLE: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA	69
Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation	67
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	67
Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study	67
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	66
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	66
Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting	66
Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study	64
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	63
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	63
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	62
Targeting CD47 for cancer immunotherapy	62
Payload diversification: a key step in the development of antibody–drug conjugates	62
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy	62
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel	62
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study	61
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma	61
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	60
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study	60
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	60
Born to survive: how cancer cells resist CAR T cell therapy	58
Targeting neddylation E2s: a novel therapeutic strategy in cancer	57
Targeting MCL-1 in cancer: current status and perspectives	54
Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients	53
Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy	53
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial	53
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial	53
A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes	53
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant	52
DTX-P7, a peptide–drug conjugate, is highly effective for non-small cell lung cancer	52
Momelotinib: an emerging treatment for myelofibrosis patients with anemia	51
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	51
Landscape of biallelic DNMT3A mutant myeloid neoplasms	51
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	49
Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers	49
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer	49
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia	49
How we treat primary immune thrombocytopenia in adults	48
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	48
Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis	48
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	48
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?	48
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response	46
Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors	46
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia	46
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase	45
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	45
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study	45
Critical role of the gut microbiota in immune responses and cancer immunotherapy	45
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma	44
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	44
Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies	43
Long non-coding RNAs in brain tumors: roles and potential as therapeutic targets	43

Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	43
Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution	43
Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells	43
Recent advances in therapeutic strategies for triple-negative breast cancer	42
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	42
Integrated proteogenomic characterization of urothelial carcinoma of the bladder	41
Liquid biopsy: current technology and clinical applications	41
The potential role of N7-methylguanosine (m7G) in cancer	41
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia	41
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling	40
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy	40
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	40
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study	40
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	39
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers	39
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma	39
Next generation of immune checkpoint inhibitors and beyond	39
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	38
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial	38
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers	38
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma	38
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	38
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	38
Personalized nanovaccines for treating solid cancer metastases	37
Advances in targeting histone deacetylase for treatment of solid tumors	37
Consensus, debate, and prospective on pancreatic cancer treatments	37
CAR-T cells and BiTEs in solid tumors: challenges and perspectives	37
Ferroptosis: principles and significance in health and disease	37
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study	37
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias	36
Hemophagocytic lymphohistiocytosis after COVID-19 vaccination	36
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	36
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	36
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression	36
Emerging strategies to target RAS signaling in human cancer therapy	35
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	35
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma	35
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	34
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN	34
Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma	34
Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification	34
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies	34
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	34
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	34
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	33
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	33
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia	33
Correction: A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1	33
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel	33
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	33
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients	32
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022	32
GSK3-beta as a candidate therapeutic target in soft tissue sarcomas	32
Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins	32
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting	32
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma	32
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study	32
SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism	31
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities	31
PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation	31
Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement	31
Vaccines: a promising therapy for myelodysplastic syndrome	31
Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference	31
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	30
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	30
The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer	30
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair	29
Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors	29
Lipid-based nanosystems: the next generation of cancer immune therapy	29
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study	29
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies	28
Impact of frontline treatment approach on outcomes of myeloid blast phase CML	28
The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990–2019: a population-based study	28
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	28
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks	27
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer	27
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk	27
FGFR-TKI resistance in cancer: current status and perspectives	27
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials	26
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications	26
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies	26
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors	26
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment	26
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application	26
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2	26
Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers	25
Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis	25
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	25
Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma	25
Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination	25
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia	24
3D chromatin architecture and transcription regulation in cancer	24
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents	24
The emerging role of KDM5A in human cancer	24
Current and future immunotherapeutic approaches in pancreatic cancer treatment	23